Quality statement 2: Staging (colon cancer)

Quality statement

People with colon cancer are offered contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis to determine the stage of the disease.

Quality measure

Structure: Evidence of local arrangements to ensure people with colon cancer are offered contrast-enhanced CT of the chest, abdomen and pelvis to determine the stage of the disease.

Process: Proportion of people with colon cancer who receive contrast-enhanced CT of the chest, abdomen and pelvis to determine the stage of the disease.

Numerator – the number of people in the denominator who receive contrast-enhanced CT of the chest, abdomen and pelvis to determine the stage of the disease.

Denominator – the number of people with colon cancer without contraindications to contrast-enhanced CT of the chest, abdomen and pelvis.

What the quality statement means for each audience

Service providers ensure systems are in place for people with colon cancer to be offered contrast-enhanced CT of the chest, abdomen and pelvis to determine the stage of the disease.

Healthcare professionals offer people with colon cancer contrast-enhanced CT of the chest, abdomen and pelvis to determine the stage of the disease.

Commissioners ensure they commission services that offer people with colon cancer contrast-enhanced CT of the chest, abdomen and pelvis to determine the stage of the disease.

People with colon cancer are offered a CT scan of the chest, abdomen and pelvis to estimate the spread of the disease.

Source guidance

NICE clinical guideline 131 recommendation 1.1.2.1 (key priority for implementation).

Data source

Structure: Local data collection.

Process: Local data collection. The National Bowel Cancer Audit records CT scan results, classified as normal liver, liver metastases or liver uncertain. Also contained within NICE audit support for colorectal cancer (NICE clinical guideline 131): Staging, criterion 1.